Literature DB >> 25407826

Expanding the scope of fused pyrimidines as kinase inhibitor scaffolds: synthesis and modification of pyrido[3,4-d]pyrimidines.

Paolo Innocenti1, Hannah Woodward, Lisa O'Fee, Swen Hoelder.   

Abstract

Fused pyrimidine cores are privileged kinase scaffolds, yet few examples of the 2-amino-pyrido[3,4-d]pyrimidine chemotype have been disclosed in the context of kinase inhibitor programs. Furthermore, no general synthetic route has been reported to access 2-amino-pyrido[3,4-d]pyrimidine derivatives. Here we report a versatile and efficient chemical approach to this class of molecules. Our strategy involves the concise preparation of 8-chloro-2-(methylthio)pyrido[3,4-d]pyrimidine intermediates and their efficient derivatisation to give novel compounds with potential as kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25407826     DOI: 10.1039/c4ob02238f

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  5 in total

1.  FOXM1 is a therapeutic target for high-risk multiple myeloma.

Authors:  C Gu; Y Yang; R Sompallae; H Xu; V S Tompkins; C Holman; D Hose; H Goldschmidt; G Tricot; F Zhan; S Janz
Journal:  Leukemia       Date:  2015-12-09       Impact factor: 11.528

2.  Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N8-neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722).

Authors:  Hannah L Woodward; Paolo Innocenti; Kwai-Ming J Cheung; Angela Hayes; Jennie Roberts; Alan T Henley; Amir Faisal; Grace Wing-Yan Mak; Gary Box; Isaac M Westwood; Nora Cronin; Michael Carter; Melanie Valenti; Alexis De Haven Brandon; Lisa O'Fee; Harry Saville; Jessica Schmitt; Rosemary Burke; Fabio Broccatelli; Rob L M van Montfort; Florence I Raynaud; Suzanne A Eccles; Spiros Linardopoulos; Julian Blagg; Swen Hoelder
Journal:  J Med Chem       Date:  2018-09-10       Impact factor: 7.446

3.  Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.

Authors:  Chunyan Gu; Xuefang Jing; Carol Holman; Ramakrishna Sompallae; Fenghuang Zhan; Guido Tricot; Ye Yang; Siegfried Janz
Journal:  BMC Cancer       Date:  2018-11-21       Impact factor: 4.430

4.  Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens.

Authors:  Charlotte M J Wesseling; Cornelis J Slingerland; Shanice Veraar; Samantha Lok; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2021-11-12       Impact factor: 5.084

Review 5.  Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.

Authors:  Sabah Akhtar; Tayyiba A Ali; Ammara Faiyaz; Omar S Khan; Syed Shadab Raza; Michal Kulinski; Halima El Omri; Ajaz A Bhat; Shahab Uddin
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.